Citoplurikin

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameCitoplurikin
Drug Alias NameIRX-2
ClassificationBiologics > Blood components
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsOral Squamous Cell CarcinomaSolid tumoursSquamous Intraepithelial Lesions of the Cervix +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIrx Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research InstituteNational Cancer InstituteBrooklyn Immunotherapeutics Llc
Inactive CompaniesUniversity Of Southern CaliforniaEmory University
Active IndicationsOral Squamous Cell CarcinomaSolid tumoursNeoplasm Metastasis +[12] 
Inactive IndicationsSquamous Intraepithelial Lesions of the CervixOropharyngeal NeoplasmsPancreatic Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A